Severe COPDDINONCT01285180
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD
An observational study of Severe COPD, run by AstraZeneca at 2,412 sites in Germany.
Trial summary
Daxas (roflumilast) is the first oral anti-inflammatory phosphodiesterase inhibitor (PDE-4) for patients with severe chronic obstructive pulmonary disease (COPD) experiencing chronic cough and sputum and with a history of exacerbations as add-on to bronchodilator treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Severe COPD
- What is being tested?
- Daxas
- Type of treatment
- Pill or oral medicine
- How many people
- 5,472 participants
- Where
- 2,412 sitesGermany
- Study dates
- Aug 2010to Aug 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients diagnosed with severe COPD.
Main Inclusion Criteria:
- severe COPD
Main Exclusion Criteria:
- Child pugh (classified B and C)
Trial locations and contacts
2,412 sites in 1 country.
300 sites in 1 country
Germany300 sites
Nycomed Deutschland GmbH
Aachen, 52062
Nycomed Deutschland GmbH
Aachen, 52066
Nycomed Deutschland GmbH
Aachen, 52078
Nycomed Deutschland GmbH
Aachen, 52080
Nycomed Deutschland GmbH
Aalen, 73430
Nycomed Deutschland GmbH
Aalen, 73433
Nycomed Deutschland GmbH
Abensberg, 93326
Nycomed Deutschland GmbH
Achern, 77855
Nycomed Deutschland GmbH
Achim, 28832
Nycomed Deutschland GmbH
Adelebsen, 37139
Nycomed Deutschland GmbH
Adelsdorf, 91325
Nycomed Deutschland GmbH
Adenau, 53518
Nycomed Deutschland GmbH
Adendorf, 21365
Nycomed Deutschland GmbH
Adorf, 08626
Nycomed Deutschland GmbH
Ahaus, 48683
Nycomed Deutschland GmbH
Ahlden, 29693
Nycomed Deutschland GmbH
Ahlen, 59227
Nycomed Deutschland GmbH
Ahlerstedt, 21702
Nycomed Deutschland GmbH
Ahrensburg, 22926
Nycomed Deutschland GmbH
Ahrensfelde, 16356
Nycomed Deutschland GmbH
Aichach, 86551
Nycomed Deutschland GmbH
Aichhalden, 78733
Nycomed Deutschland GmbH
Aichtal, 72631
Nycomed Deutschland GmbH
Ainring, 83404
Nycomed Deutschland GmbH
Aislingen, 89344
Nycomed Deutschland GmbH
Aken, 06385
Nycomed Deutschland GmbH
Albstadt, 72459
Nycomed Deutschland GmbH
Aldenhoven, 52457
Nycomed Deutschland GmbH
Alfhausen, 49594
Nycomed Deutschland GmbH
Allersberg, 90584
Nycomed Deutschland GmbH
Alsbach-Hähnlein, 64665
Nycomed Deutschland GmbH
Alsdorf, 52477
Nycomed Deutschland GmbH
Alsenz, 67821
Nycomed Deutschland GmbH
Altdorf, 84032
Nycomed Deutschland GmbH
Altena, 58762
Nycomed Deutschland GmbH
Altenbeken, 33184
Nycomed Deutschland GmbH
Altenburg, 04600
Nycomed Deutschland GmbH
Altenholz, 24161
Nycomed Deutschland GmbH
Altenstadt, 63674
Nycomed Deutschland GmbH
Altentreptow, 17087
Nycomed Deutschland GmbH
Althengstett, 75382
Nycomed Deutschland GmbH
Altlußheim, 68804
Nycomed Deutschland GmbH
Altötting, 84503
Nycomed Deutschland GmbH
Altshausen, 88361
Nycomed Deutschland GmbH
Alzenau in Unterfranken, 63755
Nycomed Deutschland GmbH
Amberg, 92224
Nycomed Deutschland GmbH
Amelinghausen, 21385
Nycomed Deutschland GmbH
Amtsberg, 09439
Nycomed Deutschland GmbH
Anderbeck, 38836
Nycomed Deutschland GmbH
Andernach, 56626
Nycomed Deutschland GmbH
Angersdorf, 06179
Nycomed Deutschland GmbH
Anhausen, 56584
Nycomed Deutschland GmbH
Anklam, 17389
Nycomed Deutschland GmbH
Ankum, 49577
Nycomed Deutschland GmbH
Annaberg-Buchholz, 09456
Nycomed Deutschland GmbH
Annweiler am Trifels, 76855
Nycomed Deutschland GmbH
Ansbach, 91522
Nycomed Deutschland GmbH
Apen, 26689
Nycomed Deutschland GmbH
Apolda, 99510
Nycomed Deutschland GmbH
Appenweier, 77767
Nycomed Deutschland GmbH
Argenbühl, 88260
Nycomed Deutschland GmbH
Arneburg, 39596
Nycomed Deutschland GmbH
Arnsberg, 59755
Nycomed Deutschland GmbH
Arnsberg, 59821
Nycomed Deutschland GmbH
Arnschwang, 93473
Nycomed Deutschland GmbH
Artlenburg, 21380
Nycomed Deutschland GmbH
Arzberg, 95659
Nycomed Deutschland GmbH
Asbach, 53567
Nycomed Deutschland GmbH
Aschaffenburg, 63739
Nycomed Deutschland GmbH
Aschaffenburg, 63741
Nycomed Deutschland GmbH
Aschau A. Inn, 84544
Nycomed Deutschland GmbH
Aschendorf, 26871
Nycomed Deutschland GmbH
Aschersleben, 06449
Nycomed Deutschland GmbH
Aßlar, 35614
Nycomed Deutschland GmbH
Aue, 08280
Nycomed Deutschland GmbH
Auenwald, 71549
Nycomed Deutschland GmbH
Auerbach, 09392
Nycomed Deutschland GmbH
Auerbach/Vogtl., 08209
Nycomed Deutschland GmbH
Aufkirchen, 82335
Nycomed Deutschland GmbH
Augsburg, 86154
Nycomed Deutschland GmbH
Augsburg, 86156
Nycomed Deutschland GmbH
Augsburg, 86159
Nycomed Deutschland GmbH
Augsburg, 86167
Nycomed Deutschland GmbH
Augsburg, 86179
Nycomed Deutschland GmbH
Babenhausen, 64832
Nycomed Deutschland GmbH
Babensham, 83547
Nycomed Deutschland GmbH
Backnang, 71522
Nycomed Deutschland GmbH
Bad Aibling, 83043
Nycomed Deutschland GmbH
Bad Bederkesa, 27624
Nycomed Deutschland GmbH
Bad Belzig, 14806
Nycomed Deutschland GmbH
Bad Bentheim, 48455
Nycomed Deutschland GmbH
Bad Berka, 99438
Nycomed Deutschland GmbH
Bad Bevensen, 29549
Nycomed Deutschland GmbH
Bad Birnbach, 84364
Nycomed Deutschland GmbH
Bad Blankenburg, 07422
Nycomed Deutschland GmbH
Bad Bramstedt, 24576
Nycomed Deutschland GmbH
Bad Buchau, 88422
Nycomed Deutschland GmbH
Bad Doberan, 18209
Nycomed Deutschland GmbH
Bad Driburg, 33014
Nycomed Deutschland GmbH
Bad Düben, 04849
Nycomed Deutschland GmbH
Bad Dürrenberg, 06231
Nycomed Deutschland GmbH
Bad Dürrheim, 78073
Nycomed Deutschland GmbH
Bad Essen, 49152
Nycomed Deutschland GmbH
Bad Fallingbostel, 29683
Nycomed Deutschland GmbH
Bad Feilnbach, 83075
Nycomed Deutschland GmbH
Bad Freienwalde, 16259
Nycomed Deutschland GmbH
Bad Friedrichshall, 74177
Nycomed Deutschland GmbH
Bad Grönenbach, 87730
Nycomed Deutschland GmbH
Bad Harzburg, 38667
Nycomed Deutschland GmbH
Bad Homburg, 61348
Nycomed Deutschland GmbH
Bad Kissingen, 97688
Nycomed Deutschland GmbH
Bad Klosterlausnitz, 07639
Nycomed Deutschland GmbH
Bad Kötzting, 93444
Nycomed Deutschland GmbH
Bad Kreuznach, 55543
Nycomed Deutschland GmbH
Bad Kreuznach, 55545
Nycomed Deutschland GmbH
Bad Krozingen, 79189
Nycomed Deutschland GmbH
Bad Langensalza, 99947
Nycomed Deutschland GmbH
Bad Lauterberg im Harz, 37431
Nycomed Deutschland GmbH
Bad Liebenstein, 36448
Nycomed Deutschland GmbH
Bad Liebenwerda, 04924
Nycomed Deutschland GmbH
Bad Liebenzell, 75378
Nycomed Deutschland GmbH
Bad Lippspringe, 33175
Nycomed Deutschland GmbH
Bad Mergentheim, 97980
Nycomed Deutschland GmbH
Bad Nauheim, 61231
Nycomed Deutschland GmbH
Bad Neuenahr-Ahrweiler, 53474
Nycomed Deutschland GmbH
Bad Neustadt an der Saale, 97616
Nycomed Deutschland GmbH
Bad Oeynhausen, 32547
Nycomed Deutschland GmbH
Bad Oldesloe, 23843
Nycomed Deutschland GmbH
Bad Rappenau, 74906
Nycomed Deutschland GmbH
Bad Reichenhall, 83435
Nycomed Deutschland GmbH
Bad Rippoldsau-Schapbach, 77776
Nycomed Deutschland GmbH
Bad Rothenfelde, 49214
Nycomed Deutschland GmbH
Bad Saarow, 15526
Nycomed Deutschland GmbH
Bad Salzuflen, 32105
Nycomed Deutschland GmbH
Bad Salzuflen, 32107
Nycomed Deutschland GmbH
Bad Salzuflen, 32108
Nycomed Deutschland GmbH
Bad Salzungen, 36433
Nycomed Deutschland GmbH
Bad Schandau, 01814
Nycomed Deutschland GmbH
Bad Schmiedeberg, 06905
Nycomed Deutschland GmbH
Bad Schönborn, 76669
Nycomed Deutschland GmbH
Bad Schussenried, 88427
Nycomed Deutschland GmbH
Bad Schwalbach, 65307
Nycomed Deutschland GmbH
Bad Segeberg, 23795
Nycomed Deutschland GmbH
Bad Staffelstein, 96231
Nycomed Deutschland GmbH
Bad Sulza, 99518
Nycomed Deutschland GmbH
Bad Sülze, 18334
Nycomed Deutschland GmbH
Bad Tennstedt, 99955
Nycomed Deutschland GmbH
Bad Vilbel, 61118
Nycomed Deutschland GmbH
Bad Waldsee, 88339
Nycomed Deutschland GmbH
Bad Wiessee, 83707
Nycomed Deutschland GmbH
Bad Wildungen, 34537
Nycomed Deutschland GmbH
Bad Wilsnack, 19336
Nycomed Deutschland GmbH
Bad Windsheim, 91438
Nycomed Deutschland GmbH
Bad Wünnenberg, 33181
Nycomed Deutschland GmbH
Bad Zwischenahn, 26160
Nycomed Deutschland GmbH
Baden-Baden, 76530
Nycomed Deutschland GmbH
Baden-Baden, 76534
Nycomed Deutschland GmbH
Badenhausen, 37534
Nycomed Deutschland GmbH
Baesweiler, 52499
Nycomed Deutschland GmbH
Bahrdorf, 38459
Nycomed Deutschland GmbH
Baiersbronn, 72270
Nycomed Deutschland GmbH
Baindt, 88255
Nycomed Deutschland GmbH
Bakum, 49456
Nycomed Deutschland GmbH
Balingen, 72336
Nycomed Deutschland GmbH
Bamberg, 96047
Nycomed Deutschland GmbH
Bardowick, 21357
Nycomed Deutschland GmbH
Bargstedt, 21698
Nycomed Deutschland GmbH
Barleben, 39179
Nycomed Deutschland GmbH
Barnstädt, 06268
Nycomed Deutschland GmbH
Barnstorf, 49406
Nycomed Deutschland GmbH
Barsinghausen, 30890
Nycomed Deutschland GmbH
Barßel, 26676
Nycomed Deutschland GmbH
Barth, 18356
Nycomed Deutschland GmbH
Baruth, 15837
Nycomed Deutschland GmbH
Bassenheim, 56220
Nycomed Deutschland GmbH
Bassum, 27211
Nycomed Deutschland GmbH
Baunatal, 34225
Nycomed Deutschland GmbH
Bautzen, 02625
Nycomed Deutschland GmbH
Bayreuth, 95444
Nycomed Deutschland GmbH
Beckingen, 66701
Nycomed Deutschland GmbH
Beckum, 59269
Nycomed Deutschland GmbH
Beeskow, 15848
Nycomed Deutschland GmbH
Beilngries, 92339
Nycomed Deutschland GmbH
Bellheim, 76756
Nycomed Deutschland GmbH
Belm, 49191
Nycomed Deutschland GmbH
Bensheim, 64625
Nycomed Deutschland GmbH
Berching, 92334
Nycomed Deutschland GmbH
Berchtesgaden, 83471
Nycomed Deutschland GmbH
Berg, 82335
Nycomed Deutschland GmbH
Bergen auf Rügen, 18528
Nycomed Deutschland GmbH
Bergfelde, 16562
Nycomed Deutschland GmbH
Bergisch Gladbach, 51465
Nycomed Deutschland GmbH
Bergisch Gladbach, 51467
Nycomed Deutschland GmbH
Bergisch Gladbach, 51469
Nycomed Deutschland GmbH
Bergkamen, 59192
Nycomed Deutschland GmbH
Bergrheinfeld, 97493
Nycomed Deutschland GmbH
Bergtheim, 97241
Nycomed Deutschland GmbH
Berkatal, 37297
Nycomed Deutschland GmbH
Berlin, 10119
Nycomed Deutschland GmbH
Berlin, 10178
Nycomed Deutschland GmbH
Berlin, 10179
Nycomed Deutschland GmbH
Berlin, 10243
Nycomed Deutschland GmbH
Berlin, 10247
Nycomed Deutschland GmbH
Berlin, 10249
Nycomed Deutschland GmbH
Berlin, 10315
Nycomed Deutschland GmbH
Berlin, 10367
Nycomed Deutschland GmbH
Berlin, 10369
Nycomed Deutschland GmbH
Berlin, 10405
Nycomed Deutschland GmbH
Berlin, 10407
Nycomed Deutschland GmbH
Berlin, 10409
Nycomed Deutschland GmbH
Berlin, 10437
Nycomed Deutschland GmbH
Berlin, 10439
Nycomed Deutschland GmbH
Berlin, 10551
Nycomed Deutschland GmbH
Berlin, 10555
Nycomed Deutschland GmbH
Berlin, 10557
Nycomed Deutschland GmbH
Berlin, 10587
Nycomed Deutschland GmbH
Berlin, 10625
Nycomed Deutschland GmbH
Berlin, 10627
Nycomed Deutschland GmbH
Berlin, 10707
Nycomed Deutschland GmbH
Berlin, 10709
Nycomed Deutschland GmbH
Berlin, 10711
Nycomed Deutschland GmbH
Berlin, 10713
Nycomed Deutschland GmbH
Berlin, 10717
Nycomed Deutschland GmbH
Berlin, 10719
Nycomed Deutschland GmbH
Berlin, 10777
Nycomed Deutschland GmbH
Berlin, 10783
Nycomed Deutschland GmbH
Berlin, 10789
Nycomed Deutschland GmbH
Berlin, 10827
Nycomed Deutschland GmbH
Berlin, 10961
Nycomed Deutschland GmbH
Berlin, 10967
Nycomed Deutschland GmbH
Berlin, 10969
Nycomed Deutschland GmbH
Berlin, 10997
Nycomed Deutschland GmbH
Berlin, 10999
Nycomed Deutschland GmbH
Berlin, 12043
Nycomed Deutschland GmbH
Berlin, 12047
Nycomed Deutschland GmbH
Berlin, 12049
Nycomed Deutschland GmbH
Berlin, 12051
Nycomed Deutschland GmbH
Berlin, 12055
Nycomed Deutschland GmbH
Berlin, 12099
Nycomed Deutschland GmbH
Berlin, 12101
Nycomed Deutschland GmbH
Berlin, 12103
Nycomed Deutschland GmbH
Berlin, 12109
Nycomed Deutschland GmbH
Berlin, 12157
Nycomed Deutschland GmbH
Berlin, 12159
Nycomed Deutschland GmbH
Berlin, 12163
Nycomed Deutschland GmbH
Berlin, 12165
Nycomed Deutschland GmbH
Berlin, 12205
Nycomed Deutschland GmbH
Berlin, 12247
Nycomed Deutschland GmbH
Berlin, 12277
Nycomed Deutschland GmbH
Berlin, 12279
Nycomed Deutschland GmbH
Berlin, 12307
Nycomed Deutschland GmbH
Berlin, 12347
Nycomed Deutschland GmbH
Berlin, 12349
Nycomed Deutschland GmbH
Berlin, 12357
Nycomed Deutschland GmbH
Berlin, 12459
Nycomed Deutschland GmbH
Berlin, 12555
Nycomed Deutschland GmbH
Berlin, 12557
Nycomed Deutschland GmbH
Berlin, 12559
Nycomed Deutschland GmbH
Berlin, 12587
Nycomed Deutschland GmbH
Berlin, 12621
Nycomed Deutschland GmbH
Berlin, 12623
Nycomed Deutschland GmbH
Berlin, 12627
Nycomed Deutschland GmbH
Berlin, 12629
Nycomed Deutschland GmbH
Berlin, 12679
Nycomed Deutschland GmbH
Berlin, 12681
Nycomed Deutschland GmbH
Berlin, 12683
Nycomed Deutschland GmbH
Berlin, 12689
Nycomed Deutschland GmbH
Berlin, 13051
Nycomed Deutschland GmbH
Berlin, 13055
Nycomed Deutschland GmbH
Berlin, 13057
Nycomed Deutschland GmbH
Berlin, 13086
Nycomed Deutschland GmbH
Berlin, 13156
Nycomed Deutschland GmbH
Berlin, 13187
Nycomed Deutschland GmbH
Berlin, 13347
Nycomed Deutschland GmbH
Berlin, 13349
Nycomed Deutschland GmbH
Berlin, 13353
Nycomed Deutschland GmbH
Berlin, 13357
Nycomed Deutschland GmbH
Berlin, 13359
Nycomed Deutschland GmbH
Berlin, 13403
Nycomed Deutschland GmbH
Berlin, 13407
Nycomed Deutschland GmbH
Berlin, 13409
Nycomed Deutschland GmbH
Berlin, 13437
Nycomed Deutschland GmbH
Berlin, 13439
Nycomed Deutschland GmbH
Berlin, 13465
Nycomed Deutschland GmbH
Berlin, 13507
Nycomed Deutschland GmbH
Berlin, 13583
Nycomed Deutschland GmbH
Berlin, 13585
Nycomed Deutschland GmbH
Berlin, 13591
Nycomed Deutschland GmbH
Berlin, 13595
Nycomed Deutschland GmbH
Berlin, 13597
Nycomed Deutschland GmbH
Berlin, 14052
Nycomed Deutschland GmbH
Berlin, 14057
Nycomed Deutschland GmbH
Berlin, 14059
Nycomed Deutschland GmbH
Berlin, 14163
Nycomed Deutschland GmbH
Berlin, 14167
Nycomed Deutschland GmbH
Berlin, 14197
Nycomed Deutschland GmbH
Bernau A. Chiemsee, 83233
Nycomed Deutschland GmbH
Bernburg, 06406
Nycomed Deutschland GmbH
Bernhardswald, 93170
Nycomed Deutschland GmbH
Bernkastel-Kues, 54470
About this study
Official title: Daxas in COPD Therapy
Daxas (roflumilast) is the first oral anti-inflammatory phosphodiesterase inhibitor (PDE-4) for patients with severe chronic obstructive pulmonary disease (COPD) experiencing chronic cough and sputum and with a history of exacerbations as add-on to bronchodilator treatment. With its mode of action Daxas can reduce exacerbations rates and improve lung function parameters which may result in a better health-related quality of life and an improved long-term management of COPD.
The aim of this non-interventional study is to evaluate data on quality of life in COPD patients in Germany in a real life medical setting. Evaluation is based on two COPD specific questionnaires to assess the patient's health status over six months. During the study, socio-demographic data and cost-of-illness data will be recorded. Daxas (tablet) will be administered once daily. The study will provide further data on the safety and tolerability of Daxas.
- Conditions
- Severe COPD
- Being tested
- Daxas
- Keywords
- COPD, Quality of life, sociodemographic data, cost-of-illness data, roflumilast, Daxas
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DaxasDrug
500 microgram, oral, once daily as add-on therapy to existing therapy
| Study group | Role | What they receive |
|---|---|---|
| DINO | Not described Receives: Drug: Daxas |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pre-/post comparison of the COPD status based on patients health status
Evaluation of treatment success by a COPD-specific patient questionnaire
Measured: after 6 months
Secondary outcomes (5)
Effectiveness during treatment
Evaluation of treatment success by a health status patient questionnaire
Measured: after 6 months
Evaluation of tolerability
assessment of adverse drug reactions
Measured: after 6 months
Evaluation of cost-of-illness data
number of consultations, sick leave, hospitalisation, number of and duration of rehab measures
Measured: before treatment
Evaluation of sociodemographic data
employment status, disease management programme
Measured: before treatment
Evaluation of symptom reduction of sputum and cough
Measured: after 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2011 (estimated)
- Study startAug 2010
- Primary completionAug 2012
- Study completionAug 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Severe COPDStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,472 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AstraZeneca AstraZeneca, Study director, AstraZeneca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01285180
- Sponsor's protocol ID
- RO-2455-402-DE
- Other IDs
- U1111-1136-8860
- Acronym
- DINO
- Status last verified
- Sep 2016
- First submitted
- 21 Jan 2011
- Last updated
- 28 Oct 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Daxas in COPD Therapy
- ClinicalTrials.gov ID
- NCT01285180
- Acronym / sponsor ID
- DINO / RO-2455-402-DE
- Conditions
- Severe COPD
- Keywords
- COPD, Quality of life, sociodemographic data, cost-of-illness data, roflumilast, Daxas
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,472 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Aug 2010
- Primary completion
- Aug 2012 (actual)
- Study completion
- Aug 2012 (actual)
- First posted
- 27 Jan 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Daxas (roflumilast) is the first oral anti-inflammatory phosphodiesterase inhibitor (PDE-4) for patients with severe chronic obstructive pulmonary disease (COPD) experiencing chronic cough and sputum and with a history of exacerbations as add-on to bronchodilator treatment. With its mode of action Daxas can reduce exacerbations rates and improve lung function parameters which may result in a better health-related quality of life and an improved long-term management of COPD.
The aim of this non-interventional study is to evaluate data on quality of life in COPD patients in Germany in a real life medical setting. Evaluation is based on two COPD specific questionnaires to assess the patient's health status over six months. During the study, socio-demographic data and cost-of-illness data will be recorded. Daxas (tablet) will be administered once daily. The study will provide further data on the safety and tolerability of Daxas.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| DINO | – | Drug: Daxas |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients diagnosed with severe COPD.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Daxas500 microgram, oral, once daily as add-on therapy to existing therapy | Drug | DINO |
Primary outcome
Pre-/post comparison of the COPD status based on patients health status
Time frame: after 6 months
Evaluation of treatment success by a COPD-specific patient questionnaire
5 secondary outcomes
Effectiveness during treatment
Time frame: after 6 months
Evaluation of tolerability
Time frame: after 6 months
Evaluation of cost-of-illness data
Time frame: before treatment
Evaluation of sociodemographic data
Time frame: before treatment
Evaluation of symptom reduction of sputum and cough
Time frame: after 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2016.
Related trials for Severe COPD
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
RecruitingPhase 3
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
Pulmonary Disease, Chronic Obstructive
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Pulmonary Disease, Chronic Obstructive
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AstraZeneca AstraZeneca study director
AstraZeneca
2,412 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Severe COPD, run by AstraZeneca at 2,412 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2,412 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pre-/post comparison of the COPD status based on patients health status (time frame: after 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2016.